Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Koranex Capital maintains a concentrated patent portfolio within the Biotechnology & Pharmaceuticals technology area. The current prosecution landscape is defined by 1 pending office action, which is being reviewed by 1 distinct examiner. This singular focus suggests a streamlined interaction with the patent office, as the entirety of the company's pending matters is localized within 1 distinct art unit.
The busiest examiner identified in the data is KRISHNAN, GANAPATHY, who is responsible for 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner handles the complete active workload for the portfolio. This concentration in 1 distinct art unit and under a single examiner allows for a consistent prosecution strategy, though it ties the portfolio's immediate progress to the specific evaluation of a single individual. Practitioners should note that the 1 distinct art unit involved represents the total breadth of the current pending technical review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KRISHNAN, GANAPATHY | 1 | 52.7% | +1.3% |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18272470 | PROCESS FOR THE SYNTHESIS OF REACTIVE CARBOHYDRATES INCLUDING ANTIGEN PRECURSORS FOR CONJUGATION WITH A CARRIER MATERIAL | KRISHNAN, GANAPATHY | 1693 | §103 | Non-Final OA | — | Pending | Jul 14, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialKoranex Capital has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Ganapathy Krishnan has the most, with 1 of Koranex Capital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
